Upcoming Science & Innovation Forum to Examine Complexities of DAT Testing

Complimentary registration is available for an upcoming Science & Innovation Forum focused on complexities in direct antiglobulin testing (DAT). The program will take place 2-3 p.m. ET on Thursday, June 11, and is presented by QuidelOrtho, an AABB premium corporate partner.

The session will provide an overview of DAT testing and review the role of the test in evaluating hemolysis and hemolytic anemia. The speaker will discuss traditional DAT reagents and newer technologies like column agglutination testing (CAT) using FDA-approved data. The program will also examine testing algorithms, predictive value and the clinical significance of DAT results, incorporating findings from recent publications.

Registration is complimentary but required to attend.